Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Chemotherapy + Surgery for Recurrent Nasopharyngeal Carcinoma
NCT05011227Phase 2Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Aug 2021
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Overall Survival at 4 years. Started Aug 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05011227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011227.